Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 1.58% and Operating profit at -160.01% over the last 5 years
2
The company has declared Negative results for the last 9 consecutive quarters
3
With ROE of -4.17%, it has a risky valuation with a 1.52 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 10,955 Million (Mid Cap)
NA (Loss Making)
NA
1.04%
0.24
-4.64%
1.69
Revenue and Profits:
Net Sales:
2,247 Million
(Quarterly Results - Mar 2026)
Net Profit:
104 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.48%
0%
-10.48%
6 Months
30.91%
0%
30.91%
1 Year
42.98%
0%
42.98%
2 Years
41.07%
0%
41.07%
3 Years
-19.5%
0%
-19.5%
4 Years
-43.17%
0%
-43.17%
5 Years
-39.74%
0%
-39.74%
Dian Diagnostics Group Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.58%
EBIT Growth (5y)
-160.01%
EBIT to Interest (avg)
7.00
Debt to EBITDA (avg)
1.18
Net Debt to Equity (avg)
0.23
Sales to Capital Employed (avg)
1.15
Tax Ratio
75.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
19.28%
ROE (avg)
19.22%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.52
EV to EBIT
-136.58
EV to EBITDA
19.88
EV to Capital Employed
1.40
EV to Sales
1.08
PEG Ratio
NA
Dividend Yield
1.16%
ROCE (Latest)
-1.03%
ROE (Latest)
-4.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
2,247.00
2,530.40
-11.20%
Operating Profit (PBDIT) excl Other Income
192.60
168.20
14.51%
Interest
32.70
52.50
-37.71%
Exceptional Items
2.10
-8.00
126.25%
Consolidate Net Profit
104.20
-36.40
386.26%
Operating Profit Margin (Excl OI)
85.70%
13.90%
7.18%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -11.20% vs -3.75% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 386.26% vs -136.47% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
10,064.60
12,166.60
-17.28%
Operating Profit (PBDIT) excl Other Income
1,026.70
1,226.90
-16.32%
Interest
176.10
221.70
-20.57%
Exceptional Items
-74.40
-424.20
82.46%
Consolidate Net Profit
145.60
-169.20
186.05%
Operating Profit Margin (Excl OI)
45.00%
41.20%
0.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -17.28% vs -9.03% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 186.05% vs -129.09% in Dec 2024
About Dian Diagnostics Group Co. Ltd. 
Dian Diagnostics Group Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






